Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Rhythm Pharmaceuticals, Inc. - Common Stock
(NQ:
RYTM
)
101.15
-3.86 (-3.68%)
Streaming Delayed Price
Updated: 3:06 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Rhythm Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
↗
April 10, 2024
Via
Benzinga
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
April 01, 2024
-- Proceeds from financing and existing cash on-hand sufficient to fund planned operations into 2026 --
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
7 Stocks That Will Drive the Weight Loss Drugs Market
March 28, 2024
The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.
Via
MarketBeat
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
March 25, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Analyst Expectations For Rhythm Pharmaceuticals's Future
↗
February 22, 2024
Via
Benzinga
Preview: Rhythm Pharmaceuticals's Earnings
↗
February 21, 2024
Via
Benzinga
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
↗
January 25, 2024
Via
Benzinga
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
March 11, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
March 06, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
February 22, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
The Analyst Verdict: Rhythm Pharmaceuticals In The Eyes Of 7 Experts
↗
January 04, 2024
Via
Benzinga
Analyst Expectations for Rhythm Pharmaceuticals's Future
↗
December 07, 2023
Via
Benzinga
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
February 22, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
February 08, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
February 07, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 22, 2024
↗
February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
Via
Benzinga
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
January 31, 2024
Company to participate in fireside chats at Guggenheim’s 6th Annual Biotechnology Conference on Feb. 7 and TD Cowen 44th Annual Health Care Conference on March 5
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
2 biotechs with promising weight-loss drugs coming
January 16, 2024
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co.
Via
MarketBeat
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
January 12, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
January 04, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
January 04, 2024
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
December 15, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
December 13, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma's Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trial
↗
December 06, 2023
During the R&D event for investors, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and...
Via
Benzinga
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
December 06, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
November 13, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
November 07, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)
November 02, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
October 25, 2023
From
Rhythm Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 7, 2023
↗
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
